Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GUSB | P08236 | 2/20 | 0.35 |
| ▸ | EBP | Q15125 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719933 | 1.00 | USP2 (0.47) | USP2GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL718237 | 0.91 | USP2 (0.41) | USP2GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL26940946 | 0.89 | USP2 (0.46) | USP2GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL26941612 | 0.87 | CARM1 (0.41) | USP2GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL20333633 | 0.86 | USP2 (0.43) | USP2GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL21120540 | 0.85 | USP2 (0.46) | USP2KDM4ESMN1; SMN2LMNA | |
| SCHEMBL21348493 | 0.85 | CARM1 (0.44) | USP2GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL21730510 | 0.85 | HRH3 (0.44) | USP2GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL21730428 | 0.85 | HRH3 (0.44) | USP2GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL15805642 | 0.84 | GNAI3 (0.43) | USP2GNAI3GNAO1GNAI1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384508-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-06-19 | — | — | EP | claimed |
| WO-2024031051-A1 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-02-08 | — | — | WO | claimed |
| EP-4175967-A2 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation (US) | 2023-05-10 | — | — | EP | claimed |
| WO-2023018990-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022006368-A2 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation (US) | 2022-01-06 | — | — | WO | claimed |
| US-10968240-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2021-04-06 | — | — | US | claimed |
| US-10155780-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2018-12-18 | — | — | US | claimed |
| US-20170029448-A1 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVEDDELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2017-02-02 | — | — | US | claimed |
| EP-2696678-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Molecular Transfer, Inc. (US) | 2014-02-19 | — | — | EP | claimed |
| WO-2013158127-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2013-10-24 | — | — | WO | claimed |
| EP-2015780-B1 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | MOLECULAR TRANSFER INC (US) | 2012-12-12 | — | — | EP | claimed |
| WO-2012142622-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2012-10-18 | — | — | WO | claimed |
| US-7915230-B2 | Reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER (US) | 2009-01-22 | — | — | US | claimed |
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12037600-B2 | Transfection complexes and methods of using the same | MOLECULAR TRANSFER, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024145435-A2 | LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER (US) | 2009-01-22 | — | — | US | disclosed |
| EP-2015780-A2 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | Molecular Transfer, Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007130073-A2 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | USP2 3480/4885GNAI3 1825/4885GNAO1 3482/4885 |
| US-10968240-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | USP2 3480/4885GNAI3 1825/4885GNAO1 3482/4885 |
| US-10155780-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | USP2 3696/4885GNAI3 1304/4885GNAO1 3143/4885 |
| US-20170029448-A1 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVEDDELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | PHOSPHO1, PLTP, MBOAT7 | USP2 3725/4885GNAI3 1147/4885GNAO1 3008/4885 |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | FUS, PHAX, PICALM | USP2 3503/4885GNAI3 1694/4885GNAO1 3683/4885 |
| US-12037600-B2 | Transfection complexes and methods of using the same | TIAL1, NPC1L1, LIPA | USP2 4325/4885GNAI3 1083/4885GNAO1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.